Extended Data Table 2 Subgroup efficacy analysis by PD-L1/TROP2 expression and histology

From: First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial

  1. Data cutoff date: May 27, 2024.
  2. aPD-L1 expression was assessed at a central lab with PD-L1 IHC 22C3 pharmDx.
  3. bTROP2 expression was assessed at a central lab using the EPR20043 antibody.
  4. cIncluding confirmed PR/CR and response pending confirmation. ORR was calculated based on the full analysis set population.
  5. dDCR was defined as BOR of CR + PR + SD ≥ 6 weeks. DCR was calculated based on the full analysis set population.
  6. PD-L1, programmed cell death ligand 1; TPS, tumor proportion score; ORR, objective response rate; DCR, disease control rate; mo, month; PFS, progression-free survival; CI, confidence interval.
Back to article page